Ekso Bionics partners with NSM as exclusive distributor for the Ekso Indego Personal exoskeleton, enhancing mobility solutions for spinal cord injury patients.
Quiver AI Summary
Ekso Bionics Holdings, Inc. has announced a partnership with National Seating & Mobility (NSM) to be the exclusive distributor of its Ekso Indego® Personal exoskeleton device within the complex rehabilitation technology (CRT) sector in the U.S. This wearable exoskeleton assists individuals with spinal cord injuries in standing and walking independently, featuring a modular design that allows for easy use without assistance. Ekso Indego Personal is recognized for being the lightest commercial exoskeleton on the market and offers advanced features that enable faster walking speeds. Both companies aim to enhance accessibility to innovative mobility solutions, with NSM leveraging its extensive experience and infrastructure in CRT to broaden the distribution of this life-changing technology.
Potential Positives
- Ekso Bionics has entered into an exclusive distribution agreement with National Seating & Mobility (NSM), expanding the reach of its Ekso Indego® Personal device within the complex rehabilitation technology industry in the U.S.
- The partnership with NSM, a trusted provider in mobility solutions, is expected to enhance accessibility to the innovative Ekso Indego Personal device for individuals with spinal cord injuries, promoting greater independence and mobility.
- Ekso Indego Personal is highlighted as the only known portable exoskeleton with a modular design, potentially drawing interest from healthcare providers and patients seeking advanced rehabilitation technologies.
- The press release positions Ekso Bionics well within a strategic growth trajectory by leveraging NSM's established credibility and infrastructure in the complex rehab technology market.
Potential Negatives
- The press release heavily relies on forward-looking statements, which warn investors that actual results may differ materially from the company's projections, indicating potential uncertainty regarding future performance.
- There is a noted risk expressed regarding the company's ability to secure adequate financing and future reimbursements from CMS, which could hinder their operations and growth potential.
- The press release includes disclaimers about risks related to product liability, recalls, and warranty claims, suggesting possible vulnerabilities in their product offerings that could impact the company's reputation and financial stability.
FAQ
What is the Ekso Indego Personal device?
The Ekso Indego Personal is a wearable powered exoskeleton that aids individuals with spinal cord injuries to stand and walk independently.
Who has been named the distributor for Ekso Indego Personal?
National Seating & Mobility (NSM) has been named the exclusive distributor for the Ekso Indego Personal device within the complex rehabilitation technology industry in the U.S.
What makes Ekso Indego Personal unique?
It is the only known portable exoskeleton with a modular quick connect design, allowing users to easily put it on or take it off.
How does Ekso Indego Personal benefit users?
The device enables faster walking speeds and grants increased independence for individuals with spinal cord injuries.
What is the mission of National Seating & Mobility?
NSM aims to enhance quality of life by providing advanced mobility solutions, including the distribution of cutting-edge technologies like Ekso Indego Personal.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EKSO Hedge Fund Activity
We have seen 9 institutional investors add shares of $EKSO stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 2,167,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $2,513,720
- CRESSET ASSET MANAGEMENT, LLC added 215,615 shares (+71.9%) to their portfolio in Q3 2024, for an estimated $250,113
- GEODE CAPITAL MANAGEMENT, LLC added 31,485 shares (+23.2%) to their portfolio in Q3 2024, for an estimated $36,522
- GOLDEN STATE WEALTH MANAGEMENT, LLC added 19,505 shares (+inf%) to their portfolio in Q4 2024, for an estimated $11,898
- ATRIA WEALTH SOLUTIONS, INC. removed 12,667 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $7,726
- XTX TOPCO LTD removed 10,344 shares (-48.2%) from their portfolio in Q3 2024, for an estimated $11,999
- CONSOLIDATED PORTFOLIO REVIEW CORP added 10,199 shares (+inf%) to their portfolio in Q4 2024, for an estimated $6,221
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN RAFAEL, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named National Seating & Mobility (“NSM”), a leading provider of complex rehabilitation technology (“CRT”), mobility and accessibility solutions, as the Company’s exclusive Ekso Indego
®
Personal device distributor within the CRT industry in the United States.
Ekso Indego Personal is a wearable lower extremity powered exoskeleton that enables certain individuals living with spinal cord injuries (“SCIs”) with the ability to stand and walk independently. It is the only known portable exoskeleton device to offer a modular quick connect design, which was engineered to allow users to put on and take off the device without assistance. Ekso Indego Personal is the lightest known commercial exoskeleton available offering ease of handling, transportation, and storage. Also offering an advanced gait mode, individuals with a SCI using the device have been shown to reach faster walking speeds, granting them a new level of independence in the community.
“We are excited to expand the distribution of the Ekso Indego Personal device through this strategic commercial partnership with NSM,” commented Scott Davis, the Company’s Chief Executive Officer. “Both companies see a world where people have widespread access to innovative technologies that allow them to rethink their current physical limitation. We are looking forward to working with NSM to make that a reality. And as a fast-growing, well-established company in the CRT space, NSM’s proven expertise and robust infrastructure are well aligned with our growth strategy.”
“NSM is committed to investing in resources and partnerships that enable us to bring the most advanced mobility and accessibility solutions to those we serve,” said Crispin Teufel, CEO of NSM. “We are proud to partner with Ekso Bionics to expand access to the life-changing Ekso Indego device to those who rely on CRT equipment and can benefit from the mobility and therapy this innovative technology provides.”
“We will apply both our expertise in providing one-of-a-kind mobility technologies for individuals with various conditions, and our experience with insurance submissions through our vast panel of insurance partners, to help bring Ekso Indego Personal to more people who could benefit from standing and walking in addition to wheeled mobility,” added Mr. Teufel.
About Ekso Bionics
®
Ekso Bionics
®
is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit:
www.eksobionics.com
or follow @EksoBionics on X.
About National Seating & Mobility
With a network of 180+ locations across the U.S. and Canada, National Seating & Mobility (NSM) is North America’s largest and most trusted provider of comprehensive mobility solutions including complex rehab technology (CRT), home and vehicle accessibility, and full-service maintenance and repair. NSM has been advancing independence and enhancing the quality of life of individuals who use mobility solutions for more than 30 years. The company has more than 2,400 dedicated team members who support more than 250,000 mobility solutions each year. Since 2006, NSM is the only national mobility solutions provider that is accredited by The Joint Commission and voluntarily undergoes a rigorous review process every few years to ensure and validate the company’s commitment to providing safe, quality care for our valued customers. For more information visit
www.nsm-seating.com
.
Forward-Looking Statements
Any statement contained in this press release that does not describe historical facts may constitute a forward-looking statement. Forward-looking statements may include, without limitation, statements regarding the ability of National Seating & Mobility to distribute the Company’s Ekso Indego Personal device within the complex rehabilitation technology industry in the United States, and the Company’s ability to bolster demand for its technology and execute on its long-term growth strategy. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund and grow the Company's operations and to develop or enhance the Company’s technology, the Company’s inability to obtain future reimbursements from CMS in a timely manner and at the expected reimbursement levels, the Company’s inability to obtain insurance coverage beyond CMS, the Company’s inability to obtain additional indications of use for its devices, any delay or discontinuation of the sales and distribution of Esko Indego Personal within the complex rehabilitation technology industry, or Ekso Indego Personal risks related to product liability, recall and warranty claims. These and other factors are identified and described in more detail in the Company’s filings with the U.S. Securities and Exchange Commission. To learn more about Ekso Bionics please visit the Company’s website at
www.eksobionics.com
or follow @EksoBionics on X. The Company does not undertake to update these forward-looking statements, except as required by law.
Contact:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email:
skilmer@eksobionics.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
